Source comparison
Best Tesamorelin Dosage for Visceral Fat Reduction: Comparison
1mg daily Once daily subcutaneous 5–8% VAT reduction Minimal. Occasional injection site erythema Investigational only; insufficient for clinical VAT targets Below therapeutic threshold. Detectable GH pulse but inadequate sustained IGF-1 elevation for meaningfu
This comparison does not assign a generated winner or score.
- 1mg daily
- Once daily subcutaneous
- 5–8% VAT reduction
- Minimal. Occasional injection site erythema
- Investigational only; insufficient for clinical VAT targets
- Below therapeutic threshold. Detectable GH pulse but inadequate sustained IGF-1 elevation for meaningful lipolysis
- 2mg daily
- Once daily subcutaneous (bedtime preferred)
- 15–20% VAT reduction
- Injection site reactions (10–15%), mild arthralgias (5–8%), transient peripheral oedema (3–5%)
- Standard dose for lipodystrophy, HIV-associated VAT, metabolic research protocols
- Clinical standard. Maximum efficacy-to-side-effect ratio, proven in Phase III trials (TRIM studies)
- 3mg daily
- 18–22% VAT reduction (marginal gain vs 2mg)
- Increased injection site reactions (20–25%), arthralgias (12–15%), carpal tunnel symptoms (8–10%)
- Off-label experimental use only
- Minimal efficacy gain over 2mg with disproportionate side effect increase. GHRH receptors saturated at 2mg
- 2mg every other day
- Alternate-day subcutaneous
- 8–12% VAT reduction
- Similar to 2mg daily but less consistent
- Sometimes used to mitigate side effects or reduce cost
- Suboptimal. Pulsatile pattern interrupted, insufficient sustained IGF-1 for maximal lipolysis
- The 2mg daily dose represents the point where GHRH receptor saturation drives maximal physiological GH release without crossing into supraphysiological territory. Lower doses fail to sustain IGF-1 elevation long enough to activate hormone-sensitive lipase across the entire visceral depot. Higher doses saturate the same receptors without additional benefit while increasing arthralgias and injection site reactions.